News

Baltic biotech attracts investors
Enlarge image

BusinessLithuaniaLatviaEstoniaDenmarkGermanySweden

Baltic biotech attracts investors

17.09.2012 - The very first Life Science Baltics 2012 attracted twice as many visitors than anticipated. Investors are lured by EU funds, low cost and qualified staff.

The very first Life Science Baltics conference almost 800 life science professionals visiting Vilnius. „That’s almost twice than we expected“, Jelena Suchodumceva, Senior Project Manager at Enterprise Lithuania, told EuroBiotechNews at the conference. According to the organisers from the governmental agency, more than 80% of the attendants came from non-Baltic states such as Israel, Canada, the US or EU member states. A trade fair showcasing the offerings of more than 40 companies and over 100 pre-scheduled B2B meetings reflected the huge interest to invest in the Baltic scene.

At the conference, ThermoFisher Scientific stated it will inaugurate a €16m research and production facility next week on the grounds of former Lithuanian Fermantas AB. Furthermore, Biotechpharma UAB received an €11m cash injection from EU structural funds. The money helped the Lithuanian CMO to build a state-of-the-art biopharmaceutical facility, which will become fully operational next year at Santara Valley, a brand-new life sciences-IT incubator in the country’s capital. The cluster is one of 5 high-tech valleys supported by the Lithuanian government with investments of €400m.

Prof. Dr. Vladas Bumelis, Chairman of Biotechpharma and Lithuanian biotech mastermind, said at the conference that investors are attracted by the strong knowledge base, low cost of goods and the governmental commitment to support the life sciences sector. To become a big fish within the life science scene, however, it would be essential for the many but small firms in the Baltic region to swim in formation. According to Enterprise Lithuania, the country’s life sciences industry has been skyrocketing over the last two decades with an annual growth rate of 22%, and over 80% of the production being exported. Last year, exports from the life sciences sector amounted to €276.2m. Its main export markets were Sweden (21.1% of the total); Germany (10.9%); Italy (8.1%); UK (6.%); Denmark (6.7%); Russia (4.7%); Norway (4.6%); Poland (4.3%); France (4%); and Latvia (2.7%).

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/baltic-biotech-attracts-investors.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014